Future Directions and Unanswered Questions in the Treatment of Endometrial Cancer

The panel reflects on the most important unanswered questions and future directions in endometrial cancer. Dr. Konecny highlights the promise of molecularly stratified treatment approaches targeting HER2, TROP2, B7-H4, and hormonal signaling pathways, drawing parallels to successes achieved in breast cancer. Dr. Redfern underscores the shift toward true personalized medicine enabled by biomarker-driven therapy selection. Dr. Thaker calls for greater diversity in clinical trial enrollment to ensure that efficacy data are generalizable across patient populations. Dr. Wenham contextualizes the ongoing challenges: identifying drivers of resistance in mismatch repair–deficient patients who progress, and better characterizing responsive subsets within the mismatch repair–proficient population. The panel expresses shared optimism that the conversation with patients has fundamentally changed—from discussions of terminal illness to the real possibility of chronic disease management or cure—and thanks the audience for joining the discussion.